Medical treatment of male infertility

Translational Andrology and Urology

Volumn 3, Issue 1, 2014, Pages 9-16

  Dabaja, Ali A ^a   Schlegel, Peter N ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Estrogen excess; Gonadotropins; Hypogonadotropic hypogonadism (HH); Male infertility; Medical treatment; Oligospermia

Indexed keywords

EID: 84901238177     PISSN: 22234683     EISSN: 22234691     Source Type: Journal    
DOI: 10.3978/j.issn.2223-4683.2014.01.06     Document Type: Review

References (59)

1. Irvine DS. Epidemiology and aetiology of male infertility. Hum Reprod 1998;13 Suppl 1:33-44.
2. Jarow JP, Zirkin BR. The androgen microenvironment of the human testis and hormonal control of spermatogenesis. Ann N Y Acad Sci 2005;1061:208-20.
3. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med 1991;324:93-103.
4. Zitzmann M, Nieschlag E. Hormone substitution in male hypogonadism. Mol Cell Endocrinol 2000;161:73-88.
5. Happ J, Ditscheid W, Krause U. Pulsatile gonadotropinreleasing hormone therapy in male patients with Kallmann's syndrome or constitutional delay of puberty. Fertil Steril 1985;43:599-608.
6. Blumenfeld Z, Makler A, Frisch L, et al. Induction of spermatogenesis and fertility in hypogonadotropic azoospermic men by intravenous pulsatile gonadotropinreleasing hormone (GnRH). Gynecol Endocrinol 1988;2:151-64.
7. Liu L, Banks SM, Barnes KM, et al. Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1988;67:1140-5.
8. Blumenfeld Z, Frisch L, Conn PM. Gonadotropinreleasing hormone (GnRH) antibodies formation in hypogonadotropic azoospermic men treated with pulsatile GnRH--diagnosis and possible alternative treatment. Fertil Steril 1988;50:622-9.
9. Büchter D, Behre HM, Kliesch S, et al. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol 1998;139:298-303.
10. Pitteloud N, Hayes FJ, Dwyer A, et al. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002;87:4128-36.
11. Raivio T, Falardeau J, Dwyer A, et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 2007;357:863-73.
12. Practice Committee of American Society for Reproductive Medicine, Birmingham, Alabama. Gonadotropin preparations: past, present, and future perspectives. Fertil Steril 2008;90:S13-20.
13. Warne DW, Decosterd G, Okada H, et al. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human folliclestimulating hormone and human chorionic gonadotropin. Fertil Steril 2009;92:594-604.
14. Burgués S, Calderón MD. Subcutaneous selfadministration of highly purified follicle stimulating hormone and human chorionic gonadotrophin for the treatment of male hypogonadotrophic hypogonadism. Spanish Collaborative Group on Male Hypogonadotropic Hypogonadism. Hum Reprod 1997;12:980-6.
15. Miyagawa Y, Tsujimura A, Matsumiya K, et al. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study. J Urol 2005;173:2072-5.
16. Liu PY, Baker HW, Jayadev V, et al. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome. J Clin Endocrinol Metab 2009;94:801-8.
17. Bouloux PM, Nieschlag E, Burger HG, et al. Induction of spermatogenesis by recombinant follicle-stimulating hormone (puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotropin alone. J Androl 2003;24:604-11.
18. Finkel DM, Phillips JL, Snyder PJ. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism. N Engl J Med 1985;313:651-5.
19. Burris AS, Rodbard HW, Winters SJ, et al. Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size. J Clin Endocrinol Metab 1988;66:1144-51.
20. Knuth UA, Hönigl W, Bals-Pratsch M, et al. Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial. J Clin Endocrinol Metab 1987;65:1081-7.
21. Kamischke A, Behre HM, Bergmann M, et al. Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial. Hum Reprod 1998;13:596-603.
22. Foresta C, Bettella A, Garolla A, et al. Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study. Fertil Steril 2005;84:654-61.
23. Sikaris K, McLachlan RI, Kazlauskas R, et al. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 2005;90:5928-36.
24. Gordetsky J, van Wijngaarden E, O'Brien J. Redefining abnormal follicle-stimulating hormone in the male infertility population. BJU Int 2012;110:568-72.
25. Webster J, Piscitelli G, Polli A, et al. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group. Clin Endocrinol (Oxf) 1992;37:534-41.
26. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-22.
27. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273-88.
28. Bharti S, Misro MM, Rai U. Clomiphene citrate potentiates the adverse effects of estrogen on rat testis and down-regulates the expression of steroidogenic enzyme genes. Fertil Steril 2013;99:140-8.
29. Santen RJ. Feedback control of luteinizing hormone and follicle-stimulating hormone secretion by testosterone and estradiol in men: physiological and clinical implications. Clin Biochem 1981;14:243-51.
30. Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002;167:624-9.
31. Schlegel PN. Aromatase inhibitors for male infertility. Fertil Steril 2012;98:1359-62.
32. Clark RV, Sherins RJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover. J Androl 1989;10:240-7.
33. Pavlovich CP, King P, Goldstein M, et al. Evidence of a treatable endocrinopathy in infertile men. J Urol 2001;165:837-41.
34. Saylam B, Efesoy O, Cayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril 2011;95:809-11.
35. Roth MY, Amory JK, Page ST. Treatment of male infertility secondary to morbid obesity. Nat Clin Pract Endocrinol Metab 2008;4:415-9.
36. Zumoff B, Miller LK, Strain GW. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 2003;52:1126-8.
37. Gregoriou O, Bakas P, Grigoriadis C, et al. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril 2012;98:48-51.
38. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013;369:1011-22.
39. Goldstein SR, Siddhanti S, Ciaccia AV, et al. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update 2000;6:212-24.
40. Katz DJ, Nabulsi O, Tal R, et al. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int 2012;110:573-8.
41. Whitten SJ, Nangia AK, Kolettis PN. Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate. Fertil Steril 2006;86:1664-8.
42. Hussein A, Ozgok Y, Ross L, et al. Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study. J Androl 2005;26:787-91; discussion 792-3.
43. Farmakiotis D, Farmakis C, Rousso D, et al. The beneficial effects of toremifene administration on the hypothalamicpituitary- testicular axis and sperm parameters in men with idiopathic oligozoospermia. Fertil Steril 2007;88:847-53.
44. Tsourdi E, Kourtis A, Farmakiotis D, et al. The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. Fertil Steril 2009;91:1427-30.
45. Chua ME, Escusa KG, Luna S, et al. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology 2013;1:749-57.
46. Vandekerckhove P, Lilford R, Vail A, et al. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2000;(2):CD000151.
47. Willets AE, Corbo JM, Brown JN. Clomiphene for the treatment of male infertility. Reprod Sci 2013;20:739-44.
48. Sharma RK, Agarwal A. Role of reactive oxygen species in male infertility. Urology 1996;48:835-50.
49. Saleh RA, Agarwal A. Oxidative stress and male infertility: from research bench to clinical practice. J Androl 2002;23:737-52.
50. Rolf C, Cooper TG, Yeung CH, et al. Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Hum Reprod 1999;14:1028-33.
51. Greco E, Iacobelli M, Rienzi L, et al. Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. J Androl 2005;26:349-53.
52. Paradiso Galatioto G, Gravina GL, Angelozzi G, et al. May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele? World J Urol 2008;26:97-102.
53. Ross C, Morriss A, Khairy M, et al. A systematic review of the effect of oral antioxidants on male infertility. Reprod Biomed Online 2010;20:711-23.
54. Ramasamy R, Ricci JA, Palermo GD, et al. Successful fertility treatment for Klinefelter's syndrome. J Urol 2009;182:1108-13.
55. Reifsnyder JE, Ramasamy R, Husseini J, et al. Role of optimizing testosterone before microdissection testicular sperm extraction in men with nonobstructive azoospermia. J Urol 2012;188:532-6.
56. Aydos K, Unlü C, Demirel LC, et al. The effect of pure FSH administration in non-obstructive azoospermic men on testicular sperm retrieval. Eur J Obstet Gynecol Reprod Biol 2003;108:54-8.
57. Shiraishi K, Ohmi C, Shimabukuro T, et al. Human chorionic gonadotrophin treatment prior to microdissection testicular sperm extraction in nonobstructive azoospermia. Hum Reprod 2012;27:331-9.
58. Selman H, De Santo M, Sterzik K, et al. Rescue of spermatogenesis arrest in azoospermic men after longterm gonadotropin treatment. Fertil Steril 2006;86:466-8.
59. Hussein A, Ozgok Y, Ross L, et al. Optimization of spermatogenesis-regulating hormones in patients with non-obstructive azoospermia and its impact on sperm retrieval: a multicentre study. BJU Int 2013;111:E110-4.